<DOC>
	<DOCNO>NCT00895674</DOCNO>
	<brief_summary>Renal cell carcinoma account roughly 3 % cancer . It rather aggressive cancer type , mean patient present advanced disease rather poor prognosis . When study start standard therapy patient cytokine , might accompany significant toxicity might fail therapeutic goal . In case sorafenib feasible therapeutic option . This non-interventional study create conduct collect clinical data patient ' therapy sorafenib everyday treatment schedule . The main goal study focus patient characteristic tumor status RCC treat sorafenib well treatment duration safety sorafenib everyday treatment condition .</brief_summary>
	<brief_title>Patient Characteristics Advanced Renal Cell Carcinoma Daily Practice Treatment With Nexavar</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients diagnosis advance RCC decision take investigator prescribe Sorafenib Exclusion criterion must read conjunction local product information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
</DOC>